Business / Finance

RSS

Wright Medical Group acquires BioMimetic Therapeutics

Wright Medical Group, Inc. today announced that it has completed its acquisition of BioMimetic Therapeutics, Inc. The transaction combines BioMimetic's breakthrough biologics platform and pipeline with Wright's established sales force and product portfolio, to further accelerate growth opportunities in Wright's Extremities business.

1 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

NanoViricides, Inc., announced today that it has retired the remainder of the Series C Convertible Preferred Stock previously purchased by Seaside 88, LP, with a cash payment.

27 Feb 2013

Global eye health company, Bausch + Lomb, names Robert Bertolini as president and chief financial officer

Bausch + Lomb, the global eye health company, has named Robert Bertolini as president and chief financial officer effective immediately. In this capacity, he will oversee the company's Finance, Information Technology and Global Quality and Operations (GQO) functions. Bertolini, who assumes CFO responsibilities from Brian J. Harris, will report to Bausch + Lomb's chief executive officer, Brent Saunders.

27 Feb 2013

Almost Family reports net service revenues of $87M for fourth quarter

Almost Family, Inc., a leading regional provider of home health nursing and personal care services, announced today its financial results for the three months and full year ended December 31, 2012.

27 Feb 2013

HeartWare International fourth quarter revenue increases 42% to $32.7 million

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $32.7 million for the fourth quarter ended December 31, 2012, a 42% increase compared to $23.1 million in revenue for the same period of 2011.

27 Feb 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

Glide Pharma announces completion of $21.4 million investment round

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a £14.0 million ($21.4 million) investment round.

26 Feb 2013

Kindred Healthcare fourth quarter consolidated revenues increase 2% to $1.55 billion

Kindred Healthcare, Inc. today announced its operating results for the fourth quarter and year ended December 31, 2012.

25 Feb 2013

Mindray fourth quarter net revenues increase 19.7% to $316.1 million

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the fourth quarter and full year ended December 31, 2012.

From Mindray 25 Feb 2013

Next generation deep brain stimulation (DBS) therapy to be developed by Sapiens

Sapiens Steering Brain Stimulation B.V. (Sapiens), an emerging medical technology company developing brain stimulation products, today announced that it has raised €7.5 m from the Dutch investment group INKEF Capital, in a further extension of their Series A financing round. The proceeds will be used for the development of its Steering Brain Stimulation implant and procedure solutions to treat Parkinson's disease (PD) and other functional brain disorders.

25 Feb 2013

Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances.

From Quest Diagnostics 25 Feb 2013

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

Blaze Bioscience completes $8.5 million Series A financing

Blaze Bioscience, Inc., a biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, today announced the completion of a Series A financing totaling $8.5 million and bringing the total funds raised since inception to $9.8 million.

22 Feb 2013

Majority of businesses are not adequately prepared for many types of disasters

A recent study by Saint Louis University researchers found that majority of businesses are not adequately prepared for many types of disasters, especially biological events such as a pandemic.

22 Feb 2013

Medidata Solutions fourth quarter net revenues increase 24% to $58.6 million

Medidata Solutions, a leading global provider of cloud-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the fourth quarter and full year 2012, and provided detailed financial guidance for the first quarter and full year 2013.

21 Feb 2013

Push for electronic medical records leads to profits for some companies

The approach came in 2009, in a presentation to doctors by Allscripts Healthcare Solutions of Chicago, a well-connected player in the lucrative business of digital medical records.

21 Feb 2013

Medisafe 1 Technologies intends to issue one-time special dividend to all shareholders

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company intends to issue the one-time special dividend to all existing shareholders pursuant to the perpetual license sale of technology rights to SAFECODE DRUG TECHNOLOGIES CORP.

20 Feb 2013

Healthcare Realty revenues increase to $81.3M for three months ended December 31, 2012

Healthcare Realty Trust Incorporated today announced results for the fourth quarter ended December 31, 2012.

20 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013